Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tapotoclax - Amgen

Next Previous
Drug Profile

Tapotoclax - Amgen

Alternative Names: AMG-176

Latest Information Update: 28 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amgen
  • Developer AbbVie; Amgen; BeOne Medicines; Genentech
  • Class Amides; Antineoplastics; Cyclobutanes; Cyclohexenes; Ethers; Naphthalenes; Oxazepines; Small molecules; Spiro compounds; Sulfonamides
  • Mechanism of Action MCL1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • No development reported Acute myeloid leukaemia; Haematological malignancies; Multiple myeloma; Non-Hodgkin's lymphoma

Most Recent Events

  • 28 May 2025 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in USA (PO)
  • 13 Jun 2024 Updated adverse events data from aphase I trial in Myelodysplastic syndromes presented at 29th Congress of the European Haematology Association (EHA-2024)
  • 31 May 2024 Pharmacodynamics, adverse events and efficacy data from a phase I trial in Myelodysplastic syndromes and Chronic myelomonocytic leukaemia presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top